Which has preferable earnings & valuation, PRTA or GNLX?

Genelux has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prothena $9.68M 45.21 -$244.09M -$0.84 N/A Genelux $10K 11,581.44 -$32.15M -$0.86 N/A

Is PRTA or GNLX more profitable?

Genelux has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Prothena -80.68% -16.45% -14.51% Genelux N/A -205.85% -138.79%

Does the media prefer PRTA or GNLX?

In the previous week, Prothena had 7 more articles in the media than Genelux. MarketBeat recorded 10 mentions for Prothena and 3 mentions for Genelux. Prothena's average media sentiment score of 1.16 beat Genelux's score of 0.88 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genelux 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DMAC or GNLX more profitable?

DiaMedica Therapeutics' return on equity of -77.76% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets DiaMedica Therapeutics N/A -77.76% -69.43% Genelux N/A -205.85% -138.79%

Does the media refer more to DMAC or GNLX?

In the previous week, Genelux had 2 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for Genelux and 1 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.50 beat Genelux's score of 0.88 indicating that DiaMedica Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Genelux 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GNLX or TECX more profitable?

Tectonic Therapeutic's return on equity of -35.26% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -205.85% -138.79% Tectonic Therapeutic N/A -35.26% -33.59%

Does the media refer more to GNLX or TECX?

In the previous week, Tectonic Therapeutic had 4 more articles in the media than Genelux. MarketBeat recorded 7 mentions for Tectonic Therapeutic and 3 mentions for Genelux. Genelux's average media sentiment score of 0.88 beat Tectonic Therapeutic's score of 0.27 indicating that Genelux is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate GNLX or PRTC?

Genelux presently has a consensus price target of $18.00, indicating a potential upside of 603.13%. Given Genelux's stronger consensus rating and higher possible upside, equities research analysts plainly believe Genelux is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, GNLX or PRTC?

Genelux has higher earnings, but lower revenue than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genelux $10K 11,581.44 -$32.15M -$0.86 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Is GNLX or PRTC more profitable?

PureTech Health's return on equity of 0.00% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -205.85% -138.79% PureTech Health N/A N/A N/A

Is MYGN or GNLX more profitable?

Genelux has a net margin of 0.00% compared to Myriad Genetics' net margin of -13.96%. Myriad Genetics' return on equity of -16.09% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Myriad Genetics -13.96% -16.09% -8.10% Genelux N/A -205.85% -138.79%

Does the media refer more to MYGN or GNLX?

In the previous week, Myriad Genetics and Myriad Genetics both had 3 articles in the media. Genelux's average media sentiment score of 0.88 beat Myriad Genetics' score of 0.61 indicating that Genelux is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genelux 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Genelux (GNLX) Competitors

$2.56 +0.04 (+1.59%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.54 -0.02 (-0.82%)

As of 10/2/2026 07:30 PM Eastern

Compare

GNLX vs. PRTA, DMAC, TECX, PRTC, and MYGN

Should you buy Genelux stock or one of its competitors? Genelux's main competitors and comparable companies include Prothena (PRTA), DiaMedica Therapeutics (DMAC), Tectonic Therapeutic (TECX), PureTech Health (PRTC), and Myriad Genetics (MYGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Genelux compare to Prothena?

Prothena (NASDAQ:PRTA) and Genelux (NASDAQ:GNLX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Prothena has a beta of -0.29, indicating that its share price is 129% less volatile than the broader market. Comparatively, Genelux has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

97.1% of Prothena shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 10.4% of Prothena shares are held by company insiders. Comparatively, 7.5% of Genelux shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Prothena had 7 more articles in the media than Genelux. MarketBeat recorded 10 mentions for Prothena and 3 mentions for Genelux. Prothena's average media sentiment score of 1.16 beat Genelux's score of 0.88 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genelux	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prothena currently has a consensus target price of $24.57, suggesting a potential upside of 193.92%. Genelux has a consensus target price of $18.00, suggesting a potential upside of 603.13%. Given Genelux's stronger consensus rating and higher probable upside, analysts plainly believe Genelux is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Genelux has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
Genelux	N/A	-205.85%	-138.79%

Genelux has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	45.21	-$244.09M	-$0.84	N/A
Genelux	$10K	11,581.44	-$32.15M	-$0.86	N/A

Summary

Prothena beats Genelux on 9 of the 16 factors compared between the two stocks.

How does Genelux compare to DiaMedica Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and Genelux (NASDAQ:GNLX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Genelux has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
Genelux	$10K	11,581.44	-$32.15M	-$0.86	N/A

DiaMedica Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, Genelux has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

DiaMedica Therapeutics' return on equity of -77.76% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
Genelux	N/A	-205.85%	-138.79%

DiaMedica Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 45.81%. Genelux has a consensus target price of $18.00, suggesting a potential upside of 603.13%. Given Genelux's stronger consensus rating and higher probable upside, analysts plainly believe Genelux is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Genelux had 2 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for Genelux and 1 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.50 beat Genelux's score of 0.88 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Genelux	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by insiders. Comparatively, 7.5% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Genelux beats DiaMedica Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Genelux compare to Tectonic Therapeutic?

Genelux (NASDAQ:GNLX) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

Genelux has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.28, indicating that its stock price is 228% more volatile than the broader market.

Genelux has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	11,581.44	-$32.15M	-$0.86	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A

37.3% of Genelux shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Tectonic Therapeutic had 4 more articles in the media than Genelux. MarketBeat recorded 7 mentions for Tectonic Therapeutic and 3 mentions for Genelux. Genelux's average media sentiment score of 0.88 beat Tectonic Therapeutic's score of 0.27 indicating that Genelux is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genelux	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tectonic Therapeutic	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tectonic Therapeutic's return on equity of -35.26% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-205.85%	-138.79%
Tectonic Therapeutic	N/A	-35.26%	-33.59%

Genelux presently has a consensus price target of $18.00, indicating a potential upside of 603.13%. Tectonic Therapeutic has a consensus price target of $77.80, indicating a potential upside of 245.16%. Given Genelux's higher possible upside, analysts plainly believe Genelux is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

Tectonic Therapeutic beats Genelux on 9 of the 15 factors compared between the two stocks.

How does Genelux compare to PureTech Health?

Genelux (NASDAQ:GNLX) and PureTech Health (NASDAQ:PRTC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

37.3% of Genelux shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 7.5% of Genelux shares are owned by company insiders. Comparatively, 5.3% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Genelux presently has a consensus price target of $18.00, indicating a potential upside of 603.13%. Given Genelux's stronger consensus rating and higher possible upside, equities research analysts plainly believe Genelux is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Genelux has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

PureTech Health's return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-205.85%	-138.79%
PureTech Health	N/A	N/A	N/A

Genelux has higher earnings, but lower revenue than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	11,581.44	-$32.15M	-$0.86	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

In the previous week, Genelux had 3 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for Genelux and 0 mentions for PureTech Health. PureTech Health's average media sentiment score of 1.08 beat Genelux's score of 0.88 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Genelux	Positive
PureTech Health	Positive

Summary

Genelux beats PureTech Health on 9 of the 14 factors compared between the two stocks.

How does Genelux compare to Myriad Genetics?

Myriad Genetics (NASDAQ:MYGN) and Genelux (NASDAQ:GNLX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by company insiders. Comparatively, 7.5% of Genelux shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Genelux has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.53	-$365.90M	-$1.19	N/A
Genelux	$10K	11,581.44	-$32.15M	-$0.86	N/A

Myriad Genetics presently has a consensus target price of $3.93, indicating a potential downside of 13.36%. Genelux has a consensus target price of $18.00, indicating a potential upside of 603.13%. Given Genelux's stronger consensus rating and higher possible upside, analysts plainly believe Genelux is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	3 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Genelux has a net margin of 0.00% compared to Myriad Genetics' net margin of -13.96%. Myriad Genetics' return on equity of -16.09% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-13.96%	-16.09%	-8.10%
Genelux	N/A	-205.85%	-138.79%

In the previous week, Myriad Genetics and Myriad Genetics both had 3 articles in the media. Genelux's average media sentiment score of 0.88 beat Myriad Genetics' score of 0.61 indicating that Genelux is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genelux	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Myriad Genetics has a beta of 1.64, suggesting that its share price is 64% more volatile than the broader market. Comparatively, Genelux has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

Summary

Genelux beats Myriad Genetics on 11 of the 16 factors compared between the two stocks.

Get Genelux News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNLX vs. The Competition

Export

Metric	Genelux	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$114.02M	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.64%	2.53%	16.77%
P/E Ratio	-2.98	12.93	273.77	26.04
Price / Sales	11,581.44	1,331.86	622.72	93.41
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	8.53	16.63	10.92	6.30
Net Income	-$32.15M	-$22.67M	$3.50B	$361.43M
7 Day Performance	3.23%	-3.10%	-2.07%	-1.67%
1 Month Performance	1.59%	-10.70%	-6.21%	-4.51%
1 Year Performance	-42.47%	19.46%	7.45%	2.03%

Genelux Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNLX Genelux	2.4903 of 5 stars	$2.56 +1.6%	$18.00 +603.1%	-41.7%	$114.02M	$10K	N/A	26
PRTA Prothena	3.1086 of 5 stars	$8.54 flat	$24.57 +187.7%	-16.3%	$448.12M	$9.68M	N/A	67	Positive News Insider Trade
DMAC DiaMedica Therapeutics	2.0318 of 5 stars	$8.25 -1.2%	$12.00 +45.4%	+17.6%	$444.71M	N/A	N/A	35	Positive News
TECX Tectonic Therapeutic	2.4146 of 5 stars	$22.57 -0.4%	$77.80 +244.7%	+47.8%	$441.44M	N/A	N/A	60	News Coverage Analyst Forecast
PRTC PureTech Health	0.0774 of 5 stars	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNLX) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genelux (GNLX) Competitors

GNLX vs. PRTA, DMAC, TECX, PRTC, and MYGN

How does Genelux compare to Prothena?

Summary

How does Genelux compare to DiaMedica Therapeutics?

Summary

How does Genelux compare to Tectonic Therapeutic?

Summary

How does Genelux compare to PureTech Health?

Summary

How does Genelux compare to Myriad Genetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNLX vs. The Competition

Genelux Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genelux (GNLX) Competitors

GNLX vs. PRTA, DMAC, TECX, PRTC, and MYGN

How does Genelux compare to Prothena?

Which has more volatility and risk, PRTA or GNLX?

Do institutionals & insiders have more ownership in PRTA or GNLX?

Does the media prefer PRTA or GNLX?

Do analysts recommend PRTA or GNLX?

Is PRTA or GNLX more profitable?

Which has preferable earnings & valuation, PRTA or GNLX?

Summary

How does Genelux compare to DiaMedica Therapeutics?

Which has preferable valuation & earnings, DMAC or GNLX?

Which has more risk and volatility, DMAC or GNLX?

Is DMAC or GNLX more profitable?

Do analysts rate DMAC or GNLX?

Does the media refer more to DMAC or GNLX?

Do institutionals & insiders believe in DMAC or GNLX?

Summary

How does Genelux compare to Tectonic Therapeutic?

Which has more volatility and risk, GNLX or TECX?

Which has preferable valuation and earnings, GNLX or TECX?

Do institutionals and insiders have more ownership in GNLX or TECX?

Does the media refer more to GNLX or TECX?

Is GNLX or TECX more profitable?

Do analysts rate GNLX or TECX?

Summary

How does Genelux compare to PureTech Health?

Do institutionals and insiders have more ownership in GNLX or PRTC?

Do analysts rate GNLX or PRTC?

Which has more volatility & risk, GNLX or PRTC?

Is GNLX or PRTC more profitable?

Which has higher earnings and valuation, GNLX or PRTC?

Does the media refer more to GNLX or PRTC?

Summary

How does Genelux compare to Myriad Genetics?

Do institutionals & insiders believe in MYGN or GNLX?

Which has stronger valuation & earnings, MYGN or GNLX?

Do analysts recommend MYGN or GNLX?

Is MYGN or GNLX more profitable?

Does the media refer more to MYGN or GNLX?

Which has more risk and volatility, MYGN or GNLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNLX vs. The Competition

Genelux Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools